Table 1.
Baseline Patient Demographic and Clinical Characteristics.
| Characteristics | Number (%) |
|---|---|
| Age (years), median (range) | 56 (26 -75) |
| ≥65 years, n (%) | 20 (13.5%) |
| ECOG, n (%) | |
| 0 | 107 (72.3%) |
| 1 | 41 (27.7%) |
| Menopausal status, n (%) | |
| Pre/perimenopausal | 63 (42.6%) |
| Postmenopausal | 84 (56.8%) |
| Missing | 1 (0.7%) |
| Vascular comorbidity, n (%) a | 56 (37.8%) |
| Disease stage, n (%) | |
| Stage I | 57 (38.5%) |
| Stage II | 36 (24.3%) |
| Stage III | 55 (37.2%) |
| Histology, n (%) | |
| Invasive ductal carcinoma | 133 (89.9%) |
| Invasive lobular carcinoma | 9 (6.1%) |
| Invasive carcinoma, NOS | 6 (4.0%) |
| ER positive, n (%) | 107 (72.3%) |
| HER2 positive, n (%) | 49 (33.1%) |
| Treatment setting, n (%) | |
| Adjuvant | 116 (78.4%) |
| Neoadjuvant | 32 (21.6%) |
| Chemotherapy regimen, n (%) | |
| Anthracycline-containing (AC, AC → T b ) | 136 (91.9%) |
| Non-anthracycline containing (TC b ) | 12 (8.1%) |
| Baseline AST/ALT levels | |
| <1.5 × upper normal limit | 142 (95.9%) |
| 1.5-3 × upper normal limit | 6 (4.1%) |
| Baseline WBC ≤5000 cell/mm3, n (%) | 16 (10.8%) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; NOS, not otherwise specified; ER positive, estrogen receptor positive; HER2 positive, human epidermal growth factor receptor 2 positive; AST, aspartate aminotransferase; ALT, alanine aminotransferase; WBC, white blood cell.
a
Consisted of diabetes mellitus, hypertension, hypercholesterolemia, ischemic heart disease, or peripheral arterial disease.
b
AC, doxorubicin/cyclophosphamide; AC → T, doxorubicin/cyclophosphamide followed by paclitaxel; TC, docetaxel/cyclophosphamide.